Article Details

Weekly tirzepatide confers substantial weight loss in obesity without diabetes: SURMOUNT-1

Retrieved on: 2022-06-04 21:02:12

Tags for this article:

Click the tags to see associated articles and topics

Weekly tirzepatide confers substantial weight loss in obesity without diabetes: SURMOUNT-1. View article details on hiswai:

Excerpt

Disclosures: Jastreboff reports receiving consultant or advisory fees from Boehringer Ingelheim, Eli Lilly, Intellihealth, Novo Nordisk, Pfizer and ...

Article found on: www.healio.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up